| Friend or foe?: The tumour microenvironment dilemma in colorectal cancer T Colangelo, G Polcaro, L Muccillo, G D'Agostino, V Rosato, P Ziccardi, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1867 (1), 1-18, 2017 | 111 | 2017 |
| Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients F Sabbatino, L Liguori, G Polcaro, I Salvato, G Caramori, FA Salzano, ... International journal of molecular sciences 21 (19), 7295, 2020 | 85 | 2020 |
| Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer T Colangelo, G Polcaro, P Ziccardi, B Pucci, L Muccillo, M Galgani, ... Cell death & disease 7 (2), e2120-e2120, 2016 | 81 | 2016 |
| The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells T Colangelo, G Polcaro, P Ziccardi, L Muccillo, M Galgani, B Pucci, ... Cell death & disease 7 (2), e2108-e2108, 2016 | 80 | 2016 |
| Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients F Sabbatino, V Conti, L Liguori, G Polcaro, G Corbi, V Manzo, V Tortora, ... Life 11 (2), 105, 2021 | 45 | 2021 |
| Interfering with the tumor–immune interface: making way for triazine-based small molecules as novel PD-L1 inhibitors P Russomanno, G Assoni, J Amato, VM D’Amore, R Scaglia, ... Journal of medicinal chemistry 64 (21), 16020-16045, 2021 | 21 | 2021 |
| Peritumoral immune infiltrate as a prognostic biomarker in thin melanoma F Sabbatino, G Scognamiglio, L Liguori, A Marra, AM Anniciello, ... Frontiers in Immunology 11, 561390, 2020 | 19 | 2020 |
| Bispecific antibodies: A novel approach for the treatment of solid tumors L Liguori, G Polcaro, A Nigro, V Conti, C Sellitto, F Perri, A Ottaiano, ... Pharmaceutics 14 (11), 2442, 2022 | 15 | 2022 |
| The blockade of tumoral IL1β-mediated signaling in normal colonic fibroblasts sensitizes tumor cells to chemotherapy and prevents inflammatory CAF activation NG Díaz-Maroto, G Garcia-Vicién, G Polcaro, M Bañuls, N Albert, ... International Journal of Molecular Sciences 22 (9), 4960, 2021 | 14 | 2021 |
| rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC G Polcaro, L Liguori, V Manzo, A Chianese, G Donadio, A Caputo, ... Molecular Cancer 23 (1), 63, 2024 | 11 | 2024 |
| Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series L Liguori, A Luciano, G Polcaro, A Ottaiano, M Cascella, F Perri, S Pepe, ... Biomedicines 11 (11), 2974, 2023 | 2 | 2023 |
| Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a … A Luciano, L Liguori, G Polcaro, F Sabbatino, S Pepe Clinics and Practice 13 (6), 1549-1560, 2023 | 1 | 2023 |
| 36P Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced … L Liguori, G Polcaro, V Manzo, V Pagliara, C Ferrone, G Cattaneo, ... Immuno-Oncology and Technology 24, 2024 | | 2024 |
| Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study L Liguori, G Giorgio, G Polcaro, V Pagliara, D Malandrino, F Perri, ... Frontiers in Immunology 15, 1419544, 2024 | | 2024 |
| 159P Exploring programmed death cell-1 (PD-1) single nucleotide polymorphisms (SNP) as predictive biomarkers for immune-related adverse events (irAEs) in advanced cancer … L Liguori, G Polcaro, V Manzo, V Pagliara, E DeBellis, R Martinelli, ... Annals of Oncology 35, S278, 2024 | | 2024 |
| Natural Health Products for Anti-Cancer Treatment: Evidence and Controversy V Conti, G Polcaro, E De Bellis, D Donnarumma, F De Rosa, B Stefanelli, ... Journal of Personalized Medicine 14 (7), 685, 2024 | | 2024 |
| rs822336 as a predictive biomarker for anti-PD-1/PD-L1 immunotherapy in advanced NSCLC: Unraveling molecular mechanisms G Polcaro, L Liguori, V Manzo, A Chianese, G Donadio, A Caputo, ... Cancer Research 84 (6_Supplement), 2531-2531, 2024 | | 2024 |
| The Blockade of Tumoral IL1β-Mediated Signaling in Normal Colonic Fibroblasts Sensitizes Tumor Cells to Chemotherapy and Prevents Inflammatory CAF Activation N Guillén Díaz-Maroto, G García Vicién, G Polcaro, M Bañuls, N Albert, ... International Journal of Molecular Sciences, 2021, vol. 22, num. 9, 2021 | | 2021 |
| Single nucleotide polymorphisms (SNPs) in PD-L1 as predictive biomarkers for checkpoint inhibitor based-immunotherapy in caucasian patients with advanced NSCLC F Sabbatino, G Polcaro, L Liguori, V Manzo, V Conti, JD Col, A Vergatti, ... Cancer Research 80 (16_Supplement), 3132-3132, 2020 | | 2020 |
